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Abstract
The eye attempts to limit local immune and inflammatory responses to preserve vision. This
phenomenon, known as ocular immune privilege, is mediated by a combination of local and systemic
mechanisms. While immune privilege is believed to protect the eye from day-to-day inflammatory
insults, it is not absolute and its mechanisms are still incompletely understood.
Introduction and context
Theeyehas aspecial relationship withtheimmunesystem,
known as immune privilege. The term was coined in the
1940sbySirPeterMedawar,whonoticedthatforeigntissue
grafts placed in the anterior chamber (AC) of the eye were
not rejected [1]. While the concept of immune privilege is
simple, research into its nature has revealed its highly
complex character, which is still incompletely understood
(reviewed in [2]). Multiple mechanisms combine to
maintain immune privilege:
(a) Physical barriers (efficient blood-retina barrier and
lack of efferent lymphatics) prevent free entry and exit of
cells, and even larger molecules, into and out of the eye.
The integrity of the blood-retinal barrier is routinely
measuredintheclinicbythefluoresceintestandprovides
a widely accepted measure of ocular health.Nevertheless,
the concept of sequestration of the eye from the immune
system has recently been debated, mostly on the basis of
the phenomenon known as anterior chamber-associated
immune deviation (ACAID). (See item (c) below).
(b) The inhibitory ocular microenvironment, composed of
cell-bound and soluble immunosuppressive factors within
the eye, inhibits the activity of immune-competent cells.
Thesolublefactorsincludetransforminggrowthfactor-beta
(TGF-b) (which can also be membrane-bound), neuro-
peptides such as alpha-melanocyte-stimulating hormone
(a-MSH), vasoactive intestinal peptide, and others. Ocular
resident cells directly inhibit immune cells (at least in
culture) by secreting soluble factors and by contact-
dependent mechanisms. Retinal glial Müller cells were the
first to be identified, but their inhibitory surface molecules
were not characterized [3]. The pigmented epithelia of
the retina (RPE) and the iris/ciliary body (IPE) not only
inhibitTcells,butalsoinducethemtobecomeTregulatory
(Treg) cells [4]. Surface-bound molecules involved in
these processes include CD86 [which engages cytotoxic T
lymphocyteantigen4(CTLA-4)onTcells],FasL,thrombo-
spondin, and galectins [4,5].
(c) Finally, the eye actively regulates systemic immune
responses. The classic example is ACAID, a unique and
highly orchestrated immune response to antigens injected
intotheAC.Itinvolvesmigrationfromtheeyetothespleen
of F4/80
+ antigen-presenting cells that interact with
invariant natural killer T cells and B cells and culminates
in elicitation of systemic regulatory immunity through
induction of CD4
+ afferent and CD8
+ efferent Treg cells
(reviewed in [4,6]). Proteins and even cells or cellular
fragmentswereshowntopassfromtheACdirectlyintothe
blood through a highly porous structure known as the
trabecular meshwork. While some regard this as negating
the concept of ocular antigen sequestration, elicitation of
ACAID requires puncturing of the eye with a needle and
perturbation of ocular integrity. It is therefore likely that
ACAIDismorerepresentativeofaresponsetotraumarather
thanofamechanismoftolerancetotissue-specificantigens
containedinthehealthyeye.Alesscontroversialexampleis
post-recovery tolerance, in which spleen cells from mice
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(EAU) contain regulatory activity, whose generation is
dependent on the presence of eye [7-9]. This type of
tolerance was shown to involve the melanocortin pathway
and cannot be induced in melanocortin-5 receptor knock-
out mouse, but whether it is a-MSH from the eye that is
involved has not been determined.
A highly successful application of the ocular immune
privilege is corneal transplantation. Corneal allografts
are up to 90% successful without tissue matching and
without systemic immunosuppressive therapy [10]. On
the downside, however, ocular immune privilege may
leave the eye vulnerable to autoimmunity by impeding
peripheral tolerance to eye-specific antigens sequestered
behind the blood-retinal barrier [8].
Major recent advances
While some effects of neuropeptides that help maintain
the immunoinhibitory ocular microenvironment may
be exerted directly on lymphoid cells [5], neuropeptides
may also regulate production of TGF-b within the eye.
A recent study demonstrated that immune privilege of
the eye, as evaluated by rejection of allogeneic tumor
cells, development of ACAID, and maintenance of high
TGF-b levels in aqueous humor, was lost following
removal of functional sympathetic fibers [11]. Thus,
although some neuropeptides in ocular fluids might be
produced by ocular cells themselves, sympathetic inner-
vation of the eye is critical for maintenance of the above-
mentioned manifestations of immune privilege. This
could stem from the observed effects on TGF-b as there is
no evidence from previous studies for direct effects of
neuropeptides on ACAID and related phenomena.
Recent studies addressing local regulation by pigmented
ocular epithelia identified previously unrecognized mole-
cular pathways by which they mediate T-cell suppression
and their conversion to Treg cells. Ligands for the T-cell
inhibitory receptor programmed death-1 (PD-1) were
detected on human as well as mouse RPE cells. Both the
humanARPE-19lineandprimaryhumanRPEexpressboth
PD-L1 and PD-L2, and expression on primary human RPE
was enhanced by interferon-gamma (IFN-g). In murine
RPE, PD-L1 was below detection in primary cells but was
induced by IFN-g. PD-L1 expression was functionally
relevant and negatively regulated cytokine production by
T cells. This could be reversed by blocking antibodies
to PD-L1 or by PD-1 deficiency [12,13]. RPE cells also
were found to constitutively produce CTLA-2a,
a cathepsin L (CathL) inhibitor. CD4
+ T cells exposed to
CTLA-2a-expressing RPE cells or to recombinant CTLA-2a
c o n v e r t e dt oC D 2 5
+FoxP3
+ Treg cells. Importantly, this
pathwaywasfunctionalalsoinvivoandprovidedprotection
from autoimmune uveitis in the mouse EAU model,
as demonstrated using anti-CTLA-2a antibodies and
CTLA-2a-deficient mice. CTLA-2a directly lowers CathL
activity in T cells and also promotes activation of TGF-b by
facilitating Treg conversion [14,15]. Thus, PD-1 pathway
may function in suppression of the Th1 responses and
CTLA-2a may additionally convert T cells that ‘slipped
through’ the PD-1 pathway into Treg cells. In contrast, the
T cell inhibitory activity of human IPE was shown to be
driven by a contact-mediated TGF-b-dependent mechan-
ism that could be reversed by TGFb2-siRNA (short
interfering RNA) or anti-TGF-b antibodies [16].
Future directions
The elaborate and highly redundant nature of mechan-
isms comprising ocular immune privilege seems undis-
puted. If things are so good, then why are they so bad? It
seems unreasonable that in the face of immune privilege
and in the absence of physical trauma, the eye remains
vulnerable to autoimmune uveitis in both its clinical and
experimental forms. As amply demonstrated by experi-
mental models of induced uveitis, privilege is easily
broken by even small numbers of activated T-effector
cells that have been primed in the periphery or
adoptively transferred [8]. Why are they not inactivated
or converted to Treg cells by the ocular microenviron-
ment but allowed to induce destructive inflammation?
Furthermore, spontaneous uveitis develops when there is
increased frequency of retina-specific T cells, such as in
mice lacking the transcription factor AIRE (AutoImmune
REgulator) which do not delete retina-specific cells in the
thymus or in mice expressing a foreign protein in the
retina and having T cells that carry the specific T-cell
receptor [17,18]. If retinal antigens are indeed seques-
tered, where are the T cells being primed? And if they are
not sequestered, why has privilege not resulted in
systemic tolerance? It would seem that the concept of
immune privilege needs to be further studied, refined,
and perhaps revised.
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